Serological test at CSIR-CDRI, Lucknow for screening of antibodies against corona

Lucknow: CSIR-CDRI (Central Pharmaceutical Research Institute) is conducting a research study in which people are being tested for testing antibodies against SARS-CoV-2. Serological testing was conducted from 9–11 September. Over 4.5 million people in India have been infected with the virus due to the epidemic of Corona virus (COVID-19) infection for the last 7 months, resulting in over 76,270 lives.

Dr. Sushant Kar and Dr. Amit Lahiri, the nodal scientists of this research at CSIR-CDRI, said that clinical trials conducted in India have been largely limited to people showing symptoms and coming in close contact with them. Most importantly, community testing has not yet been initiated. From the reports available from various countries it can be assumed that there are many asymptomatic (symptomatic) cases which have not been tested yet. Therefore, the burden of disease can be severe.

Dr. Carr and Dr. Lahiri also reported that, the body of a person infected with the disease produces antibodies that can help them to protect them from this infection in the future. However, it is a new virus, so the period of protection from this type of antibody is not yet known. Therefore, a long-term pan-India survey (all-India surveillance) is extremely important for serological testing to estimate not only the burden of infection using serology-based investigations, but also the amount of antibodies collected at specific intervals ( Titers) can also be assessed. This will also help us identify those who can donate their plasma to sick patients.

Professor Tapas K Kundu, Director CSIR-CDRI, said that cohort (from the batch) of such consolidated information established through the study of biological samples across India is largely to help in making clinical decisions in line with the structure of the National Health Mission. Will facilitate the development of national reference standards. At the same time it will be helpful in determining the policy related to National Health Policy. It will also help in finding solutions to many unanswered questions on the infection caused by the new corona virus.

This serological test was free and voluntary for all CSIR employees and students. Blood samples were voluntarily collected from individuals participating in this research under the supervision of doctors Dr. Shalini Gupta and Dr. Vivek Bhosle of the CDRI dispensary. The presence or absence of anti-SARS-COV2 antibody titers in blood samples of CSIR staff and students will be assessed through an ELISA-based investigation at CSIR-IGIB, New Delhi. Other biochemical parameters will also be studied to explore the correlation between cardiometabolic risk factor (risk factors) and the likelihood of recurrence of infection such as death due to heart attack after recovery of several covid patients. Is being seen This serological test project will align well with another internal program of CSIR “Phenom India – Long-term Longitudinal Composite Study of Health Outcomes” to provide a comprehensive approach.

Also read in Hindi: कोरोना के विरुद्ध एंटीबॉडी की जांच के लिए CSIR-CDRI, लखनऊ में सीरोलॉजिकल परीक्षण